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RJ 2.2.5 is an immunoselected mutant of the Burkitt lymphoma line, Raji (1).
It fails to display MHC class II antigens at the cell surface because of a lack ofHLA-
DR, -DP, and -DQ mRNAs (2, 3). The deficiency can be corrected by fusing RJ
2.2.5 cells with mouse cells expressing class II genes (3-5), or by transfecting them
with mouse genomic DNA (6). Hence, RJ 2.2.5 has a defect in some positive regula-
tory factor capable ofoperating across species barriers. We have attempted to iden-
tify the target of this factor by asking whether a cell type-specific class II gene en-
hancer can function in RJ 2.2.5. In addition, we have compared DNA-binding proteins
from Raji and RJ 2.2.5, concentrating on those that bind specifically to important
sequence elements of the class II gene enhancer.
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Materials and Methods
Cells.
￿
HA2 (short for A2-2.4c16) derives from a fusion between RJ 2.2.5 cells and mouse
splenocytes (4) and carries only two mouse chromosomes, 16 and 17 (5). TXI (short for T-
XIS5.7) bears mouse genomic DNA stably integrated into the genome. It is a secondary trans-
fectant, isolated as follows: mouse DNA was introduced into RJ 2 .2.5 cells and the class II
antigen-positive line TV S4 was selected; DNA from TV S4 was introduced into RJ 2.2.5
cells and the class II antigen-positive TXI was selected (see reference 6).
Enhancer Test Constructs.
￿
Plasmids used to assay enhancer activity are diagrammed in Fig.
1. As illustrated in the lower left-hand corner, they all contain a rabbit a-globin reporter gene
and an SV40 enhancerless promoter. Test fragments are clonedjust 5' to the SV40 promoter.
Transfection.
￿
10 ltg of plasmid DNA were transfected into 10' cells by the DEAE-Dextran
technique (7). Enhancer activity was evaluated by quantitating, 2 d after transfection, the
amount of RNA initiated at the SV40 early startsites. For each plasmid, at least three in-
dependent experiments were conducted, using two different DNA preparations.
S1 NucleaseMapping
￿
Isolation ofRNA, RNA:DNA hybridization, Sl nuclease trimming,
and analysis of the protected products on a denaturing polyacrylamide gel were performed
as previously described (8). The single-stranded probe spans positions +137 to -352 on pAO
(relative to the major transcriptional startsite), and was synthesized by the extension of a
5' end-labeled oligonucleotide on single-stranded Ml3mp8(3SV, as described (9).
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FIGURE 1.
￿
Constructs used to test enhancer function. Thecore common to all plasmids is pA101,
diagrammed at the left. pA101 consists of a reporter, the rabbit p-globin coding region, and an
enhancerless promoter, the SV40 early promoter minus the 72 by repeats (9). This construct
is transcriptionally silent in most cells, but expression can be stimulated by inserting enhancer
fragments in the polylinker immediately upstream from the promoter. The plasmids we used
arediagrammed at theright: pAO, containing the SV40 enhancer (9); PS3, containing the -2175
to +12 fragment of the MHC class II gene EQ (20); pSD212, bearing the -2175 to -1145 frag-
ment of Ea; pX3, carrying only the -215 to +12 fragment of EQ; pXD21 and pXD301, bearing
the same fragment as pX3 but with an X or Y box deletion (see reference 10 for description
of the construction of these mutants). The -2175 to +12 region of Ea is depicted in the center
of the figure: the thick line represents sequences coding for mRNA and the thin line signifies
5'-flanking sequences. Numbering begins at the major site of mRNA initiation (20). The Xho
I and Bam HI sites are artificial, replacing the Acc I and Pvu I sites normally found at -215
and +12 (see reference 10 for details). Shaded boxes indicate the TATA box and the X and Y
boxes, 14-base segments conserved in all MHC class II genes so far examined (sec references
10, 11 for details).
Gel Retardation and Methylation Interference Assays.
￿
Nuclear extracts were prepared and gel
retardation assays were performed as described. (10, 11). In short, a 1-M salt extract of nuclei
was incubated with the '12P-labeled test oligonucleotide and various amounts of poly[d(I-C)]
competitor, the free DNA and DNA:protein complexes were separated on a polyacrylamide
gel, and the resulting bands were revealed by autoradiography.
Methylation interference mapping has also been detailed (11). Briefly, `2P-labeled double-
stranded oligonucleotide was partially methylated and then incubated with nuclear extract
in thepresence ofpoly[d(I-C)]. Free and protein-bound DNA were separated, extracted, cleaved
with piperidine (A+G), and electrophoresed on a sequencing gel.
Results and Discussion
Rf 2.2.5 Does NotSupport Class II Gene Enhancer Activity.
￿
B cell-specific enhancer
activity is associated with the 5'-flanking region of the murine class II gene, Ea. The
cell type specificity and detailed localization of this enhancer are described elsewhere
(Koch et al., submitted for publication); for this study, the relevant features are: (a)
The E« enhancer is cell type specific, operating in B cells but not in fibroblasts, ep-
ithelial cells, or murine T cells. (b) This enhancer was originally identified as a frag-
ment that stimulates transcription from the enhancerless SV40 promoter in con-
structslike that diagrammed in Fig. 1. (c) Maximum stimulatory activity is associatedKOCH ET AL .
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FIGURE 2 .
￿
TheEa enhancer is inoperative in RJ 2 .2.5 . Plasmids described in Fig. 1 were trans-
fected into Raji or RJ 2.2 .5 cells . 2 d later, cytoplasmic RNA was isolated and subjected to Sl
nuclease analysis to measure the amount ofRNA initiated at the SV40 early startsites .
with the -2,175 to +12 fragment of theEa gene, a map ofwhich is also presented
in Fig . 1 . (d) If this fragment is bisected at position -1,145, both halves show en-
hancer activity. The promoter-proximal (right) half remains B cell specific ; the
promoter-distal (left) half functions in all cell types . (e) The -215 to +12 region
contributes most (or all) of the activity associated with the promoter-proximal half
of the enhancer. (f ) Deletions of theXandY boxes from the -215 to +12 fragment
abrogate enhancer function . TheX and Y boxes are conserved 14-base sequence
elements located in the -50 to -100 region of all MHC class II genes so farexam-
ined . Both conserved segments are required for efficient and accurate transcription
of the Ea gene in transgenic mice (10), and both are targets for sequence-specific
DNA-binding proteins (10-13). The Ea gene has a second copy of the X and Y
boxes, in reverse orientation, at aboutposition -1300 (Fehling,J., unpublished results) .
(g) A human class II gene enhancer exhibiting some of these features has recently
been described (14) .
It was clearly of interest to compare the activity of the Ea enhancer in Raji and
RJ 2.2.5, the mutant devoid of class II antigens . A series of plasmids were trans-
fected into both cell lines, and theRNA transcribed from each construct was quanti-
tated by S1 nuclease analysis . Fig. 2 shows that an enhancerless construct is not de-
tectably expressed in Raji cells (pA101), but that the SV40 enhancer efficiently
stimulates transcription (pA0) . The complete Ea enhancer is even more powerful
than the SV40 enhancer (pS3, -2,175 to +12) . The individual halves of theEa en-
hancer display stimulatory activity (pSD212, -2,175 to -1,145 ; pX3, -215 to +12),
but the levelofstimulation by each is less than that by the complete enhancer. Dele-1784
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￿
Correction of the deficiency in class II antigen expression restores the ability of Rj
2.2 .5 to support EQ enhancer function. (A) Cytofluorimetric analysis of MHC class II antigen
expression. HA2 derives from a fusion between Rj 2.2.5 cells and mouse splenocytes (4); the
only mousechromosomes present in these cells are 16 and 17 (5). The line TXI is a secondary
transfectant bearing mouse genomic DNA stably integrated into the genome of Rj 2 .2.5. The
staining of cells and analytical procedures on an ODAM ATC 3000 have been described (21).
Cytofluorimetric profiles are shown for unstained cells (dotted lines) or for cells stained with 40B
(smooth lines), a pan-class II antigen reagent. This mAb is an anti-mouse I-A and I-E reagent,
strongly crossreactive with humanclass II antigens (22). Note that the HA2 line shows abiphasic
distribution, dueto the spontaneous segregation of mouse chromosome 16 leading to loss ofclass
II gene expression (5). (B) Quantitation of enhancer activity. Thefour cell lines were transfected
with the plasmids depicted in Fig. 1. 2 d later, cytoplasmic RNA wasprepared and assayed by
Sl nuclease mapping. Densitometric tracings ofthe bands representing Sl-resistant hybrid were
performed and the values were normalized, taking as 100% for each cell line the value obtained
for RNA from pA0 transfected cells. The bar graphs are plots of averages from at least three
independent experiments with two different plasmid preparations.
tion ofthe X(pXD21) orY (pXD301) boxes in the -215 to +12 fragment abolishes
enhancer function. In short, the Ea enhancer operates in Raji cells quite like it does
in murine B cell lymphoma lines.
The results are quite different with Rj 2.2.5: none ofthe constructs carrying the
Ea enhancer are detectably transcribed in this mutant cell line (Fig. 2). The same
negative result has been observed in six separate experiments with two independent
preparations of plasmid DNA. As might be expected, the enhancerless construct
is not transcribed in Rj 2.2.5 cells (pA101), andthe SV40enhancer functionsas effec-
tively in this variant as it does in Raji (pA0).
R,J2.2.5 Derivations Reexpressing Class II Antigens SupportEa Enhancer Activity.
￿
Ex-
pression ofthe MHC class II genes in Rj 2.2.5 cells can be restored by fusing them
with mouse cells that express class II antigens (3-5) or by transfecting them with
mouse genomic DNA (6). We wished to determine whether this restoration of en-
dogenous class II gene activity correlated with a renewed ability to support Ea en-
hancer function.KOCH ET AL.
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Acytofluorimetric analysis of human class 11 antigen expression on two such Rj
2.2.5 derivatives is presented in Fig. 3 A . The hybrid line A2-2.4c16(HA2 for short)
is derived from a fusion between Rj 2.2.5 cells and mouse splenocytes (4, 5). It car-
ries only two mouse chromosomes, 16 and 17; chromosome 16 bears aIr-1, the locus
that complements the Rj 2.2.5 defect (5). About 30% ofthe HA2 cells display human
MHC antigens in this experiment; the others have probably lost chromosome 16,
the karyotype of the cells being somewhat unstable. The line T-XIS5.7 (T-XI for
short) is a secondary transfectant ofRj 2.2.5 that carries mouse genomic DNA in-
corporated into the genome (6). Essentially all ofthe TIM cells express high levels
of human class II antigens in this experiment.
To determine whether HA2 and TXI support Ea enhancer activity, we trans-
fected the aforementioned plasmids into them aswellasinto Raji and Rj 2.2.5 cells.
The bar graphs in Fig. 3 B show transcription levels from the different constructs
assayed in at least three experiments usingtwo independent DNA preparations. The
E« enhancer functions in HA2 cells, although the level of transcriptional stimula-
tion by the complete enhancer (pS3) is only 10% of that measured in Raji cells.
A partial explanation for this lower value is that only some of the HA2 cells carry
mouse chromosome 16. TXI cells are also permissive for Ea enhancer activity; in
this case, transcription driven bythe complete enhancer is as efficient as in Rajicells.
Rj 2.2.5 Appears to Have Normal NF-XandNF-YProteins.
￿
Rj 2.2.5 cellsthus appear
to have a defect in some factor required for Ea enhancer function. We know that
the X and Y boxes are critical for transcriptional enhancement (Figs. 2 and 3 B,
and unpublished results), and that they are targets for the sequence-specific DNA-
bindingproteinsNFXand NFY(10-13). Itwasimperative,then, todeterminewhether
these proteins are normal in Rj 2.2.5 cells.
The initialassaywas the gel-retardation orband-shift assay. A 39-bp double-stranded
oligonucleotide spanning the Y box was prepared (see Fig. 4 E for sequence) and
5' end labeled with s2P The labeled oligonucleotide and unlabeled nonspecific com-
petitor DNA were incubated with a 1-M salt extract of nuclei from either Raji or
Rj 2.2.5 cells; lastly, the resultant DNA:protein complexes were separated from free
DNA on a neutral polyacrylamide gel. Three retarded bands are evident in Fig.
4A. The most rapidlymigratingspecies is probably due to nonspecificprotein:DNA
interactionsbecause it is also observedwith a control oligonucleotide bearingrandom
sequence in place ofthe Y box (laneC, as well as with several unrelated oligos (not
shown). NF-Y2 is probably very similar (or identical) to aCCAAT box-binding pro-
teintermed NFY that we identified in nuclearextracts from murine celllines (10-12).
NF-Y1 is not found in murine extracts but occurs in all human extracts so farexam-
ined (Raji, Rj 2.2.5, HeLa, MCF7). These three retarded bands appear identical
with Raji and Rj 2.2.5 extracts, and so we are led to conclude that there must be
no gross differences in NFY.
A more sensitive assay is provided by methylation interference mapping. A gel
retardation experiment was conducted as described above except that one strand
ofthe Y oligonucleotide had been partiallymethylated. After electrophoresis, DNA
from the NF-Y1, NF-Y2, and F bands were extracted, cleaved at methylated bases,
anddisplayed on asequencinggel. Comparisonofthepatterns obtained withbound
vs. free DNA should reveal protein contact sites; if methylation ofa particular site
inhibits protein binding, that site will not appear as a band, but rather as a hole.1786
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Twopoints areclearfrom Fig. 4B. First, Yl and Y2 seem to make the same contacts
on the Y box; these are indicated on the sequence in E. Second, and more relevant
for this study, Raji and Rj 2.2.5 proteins show essentially identical contacts.
Similarly, when a 32P-labeled X box oligonucleotide is incubated with nuclear ex-
tract from either Raji or the variant, two specific DNA:protein complexes are de-
tected in the gel retardation assay (Fig. 4 C). Again, the more rapidly migrating
bands are probably due to nonspecific interactions (compare with binding to the
control oligonucleotide in lane C). Methylation interference mapping shows that
NF-X1 and NF-X2 contact a single set ofbases on the Xbox, and that thesecontacts
are the same with extracts from Raji or Rj 2.2.5 cells (Fig. 4, D and E).
Thus, by these criteria the NF-X and NFY proteins do not differ between the
two celllines. The NF-Ys are also indistinguishable on thebasis ofapparent molecular
weight ofthe intact protein and ofa protease-resistant DNA-binding core (data not
shown). We are left with the conclusion that any defect in NFX or NFY must be
quite subtle, or that these proteins are normal in Rj 2.2.5 cells. Miwa et al. (13)
have also recently shown that the Raji and Rj 2.2.5 proteins binding to X and Y
box oligonucleotides are similar in gel retardation assays, but it is not possible to
determine which ofthe proteins they detect (ifany) correspond to NFX and NFY
Conclusions.
￿
We have identified the function of a regulatory factor that is defec-
tive in Rj 2.2.5 cells; this factor is absolutely required for the activity of an MHC
class II gene enhancer. Interestingly, the Ea enhancer comprises two components,
and neither is functional in Rj 2.2.5. When class II gene expression is restored in
Rj 2.2.5 derivatives, the enhancer becomes active once again, and the two halves
are activated concomitantly. Altogether, these results suggest that the two halves of
the enhancer probably operate by a similar mechanism, using at least some of the
same factors.
This conclusion may not be surprising when one considers the architecture of
the Ea 5'-flanking region; there is an Xand Y box in the -50 to -100 region and
another pair, in reverse orientation, at around position -1,300; other sequences ad-
FIGURE 4.
￿
The NFX and NF-Y proteins ofRaji and Rj 2.2 .5 are indistinguishable. (A and C)
Gel retardation assays. For Y, a fixed amount ofextract (1 pg protein) was incubated with a 5'
end-labeled double-stranded oligonucleotide and increasing amounts of poly[d-(I-C)] compet-
itor. For X, the nuclear extract wasfirst precipitated with 50% ammonium sulphate andconcen-
trated fivefold; 7.5 ug ofprotein was used in the reaction. Uncomplexed and protein-cornplexed
DNAs were resolved on a 5% polyacrylamide gel. The test oligonucleotides span the X(C or
Y (A) boxes; the actual sequences are indicated in E. To control for nonspecific binding to the
target DNA, control oligonucleotides were made that have random sequences replacing the X
or Y box but have the same 5'- and 3'-flanking sequences. Results with these oligonucleotides
are shown in lanes c of panels A and C. Amounts of poly[d(I-C)] in lanes 1-3 were 100, 300,
and 1,000 ng in both panels. Yl and Y2 represent specific DNA/protein complexes formed on
the Yoligonucleotide; XI and X2 represent specific complexes formed on the X oligonucleotide;
F signifies uncomplexed DNA.
(B and D) Methylation interference mapping. Binding reactions and gel resolution of the
DNA/protein complexes were essentially as above, except that the reactions were scaled up and
the X and Yoligonucleotides were partially methylated with dimethylsulphate before purifica-
tion. Theexperiment was done with DNA5'-end-labeled either on the sense or antisense strand.
Uncomplexed (F) or protein-complexed (Yl, Y2, Xl, X2) DNAwere eluted from the gel, cleaved
by piperidine (G+A)anddisplayed on adenaturing gel. B shows the pattern for the Yoligonucleotide
and D shows the pattern for the Xoligonucleotide. The bases whose methylation interferes with
binding are indicated in E.1788
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jacent to the X and Y boxes are also duplicated. We know that the X and Y boxes
are very important to the promoter-proximal halfbecause deleting them from the
-215 to +12 fragment abolishes enhancer activity (Figs. 2, and 3; Koch et al., sub-
mitted for publication). Yet they are not solely responsible for enhancer function
because, alone, they do not stimulate transcription that efficiently (Koch et al., sub-
mitted for publication). The XY complex in the promoter-distal half also seems
to play some role in enhancer activity according to transfection studies but even
more certainly, other sequence motifs are critical (Koch et al., submitted for publi-
cation). Nevertheless, the X and Y boxes remain the sequence elements the most
strikingly similar between the Ea promoter-proximal and promoter-distal halves of
the enhancer.
Some enhancer factor seems to be aberrant in the mutant; yet, the most likely
candidates, NF-X and NF-Y, appear normal. It is possible that the defect in Rj 2.2.5
is a subtle mutation ofNFX or NFY that does not affect their DNA-binding charac-
teristics; is the alteration of another DNA-binding protein; is the mutation of a factor
that does not bind to DNA but interacts with NF-X, NF-Y, or another DNA-binding
protein; or is an incorrect post-translational modification of any of these proteins.
One could also envisage more remote mechanisms: local disruptions of chromatin
structure, aberrant scaffold attachment sites etcetera. In fact, such a mechanism may
be implicated by the recent finding that introduction of the ras oncogene into Rj
2 .2.5 cells at least partially restores class II gene expression (15). Whatever the exact
defect, it is not a generic one, affecting the activity of all enhancers. Immunoglob-
ulin gene expression is not extinguished, and the SV40 enhancer operates quite
efficiently in Rj 2 .2 .5 (Fig. 2). In addition, the mutant cells thrive in culture, ex-
hibiting a normal doubling time.
RJ 2.2 .5 represents the first mammalian cell mutant with a documented defect
in an enhancer factor (excluding steroid hormone receptors). Atchison and Perry
(16) have recently described a plasmacytoma that exhibits a defect in an immuno-
globulin enhancer-binding factor, but it is not excluded that this line represents a
normal stage of differentiation. The RJ 2.2.5 line should prove extremely useful in
experiments designed to unravel the mechanism ofenhancer function. Complemen-
tation analysis, by DNA transfection or by fusion with other class II deficient cell
lines (17-19), could lead to an understanding of the genetics of MHC class II gene
regulation at a level currently possible only with yeast regulatory systems.
Summary
Rj 2.2.5 is an immunoselected mutant of the Burkitt lymphoma line Raji . It fails
to display MHC class II antigens at the cell surface due to a transcriptional defect.
We have identified the function of a regulatory factor that is defective in Rj 2 .2 .5
cells; this factor is absolutely required for the activity of an MHC class II gene en-
hancer.
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